Sinemet Cr

Parkinsonism, advanced Motor fluctuations, carbon monoxide intoxication + 5 more
Treatment
6 FDA approvals
20 Active Studies for Sinemet Cr

What is Sinemet Cr

LevodopaThe Generic name of this drug
Treatment SummaryLevodopa is a drug used to treat Parkinson's disease. It is able to cross the blood-brain barrier, which allows it to increase levels of dopamine in the brain. Levodopa is usually taken with a dopa decarboxylase inhibitor like carbidopa to prevent it from being broken down until after it has crossed the blood-brain barrier. The first FDA approved product containing levodopa and carbidopa was called Sinemet and was approved in 1975.
Sinemetis the brand name
image of different drug pills on a surface
Sinemet Cr Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sinemet
Levodopa
1975
272

Approved as Treatment by the FDA

Levodopa, also called Sinemet, is approved by the FDA for 6 uses including Parkinsonism post encephalitic and manganese intoxication .
Parkinsonism post encephalitic
Used to treat Parkinsonism post encephalitic in combination with Carbidopa
manganese intoxication
Used to treat manganese intoxication in combination with Carbidopa
Parkinson's Disease
Used to treat Parkinson's Disease (PD) in combination with Carbidopa
Parkinsonism
Used to treat Parkinsonism in combination with Carbidopa
Paralysis agitans
Used to treat Paralysis agitans in combination with Carbidopa
carbon monoxide intoxication
Used to treat carbon monoxide intoxication in combination with Carbidopa

Effectiveness

How Sinemet Cr Affects PatientsLevodopa, unlike dopamine, is able to cross the blood-brain barrier. Taking a dopa decarboxylase inhibitor along with levodopa helps it pass through the blood-brain barrier, allowing more of it to reach the brain. Once it reaches the brain, it is converted to dopamine by a specific enzyme.
How Sinemet Cr works in the bodyLevodopa enters the brain, where it is changed into dopamine. This dopamine helps to stimulate special receptors in the brain, allowing it to make up for the natural decrease of dopamine in the brain.

When to interrupt dosage

The prescribed dosage of Sinemet Cr is reliant upon the determined condition, including manganese intoxication, Parkinson's Disease and Restless Legs Syndrome (RLS). The amount of dosage is contingent upon the method of delivery provided in the table below.
Condition
Dosage
Administration
Parkinsonism
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
advanced Motor fluctuations
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
carbon monoxide intoxication
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
manganese intoxication
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Parkinson's Disease
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Restless Legs Syndrome (RLS)
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Paralysis agitans
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Parkinsonism post encephalitic
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)

Warnings

Sinemet Cr Contraindications
Condition
Risk Level
Notes
Malignant Neoplasms
Do Not Combine
Pulse Frequency
Do Not Combine
cutaneous lesions
Do Not Combine
There are 20 known major drug interactions with Sinemet Cr.
Common Sinemet Cr Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Levodopa may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Levodopa may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Levodopa.
Methylene blue
Major
Levodopa may increase the serotonergic activities of Methylene blue.
Mirtazapine
Major
Levodopa may increase the serotonergic activities of Mirtazapine.
Sinemet Cr Toxicity & Overdose RiskLevodopa has not been tested for use in pregnant women. In rabbits, giving levodopa and carbidopa has resulted in smaller litters and deformities in the offspring. Taking levodopa may reduce the amount of prolactin in the body, which could make it harder to breastfeed. Levodopa can also be passed to a baby through breast milk, so it's important to consider this before giving levodopa to a nursing mother. There is not yet enough information to say whether levodopa is safe and effective for children. People over 65 may be more likely to experience side effects from taking levodopa
image of a doctor in a lab doing drug, clinical research

Sinemet Cr Novel Uses: Which Conditions Have a Clinical Trial Featuring Sinemet Cr?

48 active studies are presently being conducted to determine the efficacy of Sinemet Cr in treating Parkinson's Disease, Parkinsonism and Carbon Monoxide Intoxication.
Condition
Clinical Trials
Trial Phases
Parkinson's Disease
45 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Phase 2, Early Phase 1
manganese intoxication
0 Actively Recruiting
Paralysis agitans
0 Actively Recruiting
Restless Legs Syndrome (RLS)
1 Actively Recruiting
Not Applicable
advanced Motor fluctuations
0 Actively Recruiting
Parkinsonism post encephalitic
0 Actively Recruiting
Parkinsonism
3 Actively Recruiting
Phase 4
carbon monoxide intoxication
0 Actively Recruiting

Sinemet Cr Reviews: What are patients saying about Sinemet Cr?

5Patient Review
6/8/2021
Sinemet Cr for Parkinson's Disease
I was diagnosed with Parkinson's disease a couple of years ago and ended up bedridden as a result. After taking Sinemet for several weeks, though, I gradually became more mobile again. I'm now able to walk and even work again. There is some fatigue involved, but it comes from the disease itself rather than the medication.
5Patient Review
11/5/2007
Sinemet Cr for Parkinson's Disease
4Patient Review
5/12/2012
Sinemet Cr for Parkinson's Disease
The medication does not last very long, and sometimes I have to take it multiple times in one hour.
3Patient Review
10/28/2013
Sinemet Cr for Parkinson's Disease
The effects of this medication only last for a few hours.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sinemet cr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Sinemet CR still available?

"Merck will no longer be selling Sinemet CR 50 mg/200 mg tablets as of November 2019. Mylan will have carbidopa and levodopa extended-release tablets available as of February 2020."

Answered by AI

How many hours does Sinemet CR last?

"The lower dosage may help to reduce or eliminate unwanted side-effects, such as those related to the digestive system and heart. 'Sinemet CR' and 'Half Sinemet CR' are designed to release their active ingredients over the course of four to six hours."

Answered by AI

What is the difference between Sinemet and Sinemet CR?

"Sinemet comes in two forms: an immediate release tablet and a controlled release tablet. The immediate release tablet reaches peak levels in half an hour, while the controlled release tablet takes about two hours to reach peak levels. Both forms of Sinemet decline after reaching peak levels."

Answered by AI

What does CR mean in Sinemet?

"Its empirical formula is C10H14N2O4, and it has the following structural formula:

SINEMET CR is a combination of two drugs, carbidopa and levodopa, for the treatment of Parkinson's disease and syndrome. Carbidopa is an inhibitor of aromatic amino acid decarboxylation, and is a white, crystalline compound with a molecular weight of 244.3. Its empirical formula is C10H14N2O4, and it has the following structural formula:"

Answered by AI

Clinical Trials for Sinemet Cr

Have you considered Sinemet Cr clinical trials? We made a collection of clinical trials featuring Sinemet Cr, we think they might fit your search criteria.
Have you considered Sinemet Cr clinical trials? We made a collection of clinical trials featuring Sinemet Cr, we think they might fit your search criteria.
Have you considered Sinemet Cr clinical trials? We made a collection of clinical trials featuring Sinemet Cr, we think they might fit your search criteria.